Gå til indhold
Global sound
BackTable Urology

BackTable Urology

Ep. 341 Understanding Overactive Bladder in Male Patients with Dr. Bilal Chughtai

· 41 min.

Episodebeskrivelse

How many prostate medications and procedures should a man try before anyone checks his bladder? Dr. Bilal Chughtai has met men who worked through an alpha blocker, add-on medications, a minimally invasive prostate procedure, and even resective surgery before anyone named overactive bladder as part of the problem. On this episode of BackTable Urology, Dr. Anjali Kapur, urogynecologist at Hackensack Meridian Health, welcomes Dr. Chughtai, chief of urology at Northwell Health's Plainview and Syosset hospitals, to rethink how urologists separate overactive bladder (OAB) from benign prostatic hyperplasia (BPH) in men. Dr. Chughtai explains how he reads the storage and voiding items of the International Prostate Symptom Score (IPSS), why he usually starts with a beta-3 agonist rather than an anticholinergic, how he trims polypharmacy one medication holiday at a time, and when urodynamics helps decide whether to treat the prostate, the bladder, or both.

---

Get the BackTable apphttps://www.backtable.com/app

---

This podcast is supported by

Sumitomo Pharma America, Inc.https://www.us.sumitomo-pharma.com/

---

Timestamps

00:00 - Introduction02:37 - Initial Evaluation and First-Line Therapy06:11 - Combination Therapy and Medication Holidays09:37 - Reassessing Symptoms After an Outlet Procedure11:59 - Botox and Neuromodulation in Men15:14 - Persistent Symptoms After Prior BPH Treatment18:44 - The COURAGE Trial and Urge Incontinence23:22 - Combining Therapies and Setting Goals25:48 - Questionnaires, Bladder Diaries, and Underreporting29:05 - OAB Awareness in Primary Care31:14 - Nocturia and Sleep Apnea33:23 - Timing of Intervention and Bladder Health38:04 - Final Takeaways and Closing Remarks

---

More about this episode

The two then turn to third-line therapy in men, including intradetrusor botulinum toxin, sacral neuromodulation, and tibial nerve stimulation, and to men whose storage symptoms persist or appear after an outlet procedure. Dr. Chughtai shares what the COURAGE trial of a beta-3 agonist added to BPH therapy taught him about asking men directly about urge incontinence, along with his goal of a 50% improvement in symptoms, the limits of questionnaires and bladder diaries, his research on OAB awareness in primary care, and the link between nocturia and sleep apnea. They close on the open question of when to treat the bladder before it changes, and why counseling should inform men without threatening them.

---

Resources

Efficacy and Safety of Vibegron for Persistent Symptoms of Overactive Bladder in Men Being Pharmacologically Treated for Benign Prostatic Hyperplasia: Results From the Phase 3 Randomized Controlled COURAGE Trial. J Urol. 2024https://pubmed.ncbi.nlm.nih.gov/38708869/ Vibegron for overactive bladder in men with benign prostatic hyperplasia/obstruction: insights from the COURAGE trial. Transl Androl Urol. 2025https://pubmed.ncbi.nlm.nih.gov/40376518/ Lower Urinary Tract Symptoms Following Transurethral Resection of…

Live, seneste time: 14.041 sange på 5.809 stationer i 117 lande

Opdag verden gennem radioen

Flere måder at opdage på (7)

Hørt noget godt? Gem det, eller åbn det direkte i Spotify.

★ Artist of the week The fastest riser on the radio this week
Your song here? From € 9 per week →
Radio AltstastwelleFortsæt med at lytte